| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bipolar Disorder | 209 | 2022 | 5027 | 10.370 |
Why?
|
| Antimanic Agents | 43 | 2012 | 522 | 4.150 |
Why?
|
| Antipsychotic Agents | 56 | 2023 | 3057 | 3.360 |
Why?
|
| Antidepressive Agents | 49 | 2023 | 2838 | 2.440 |
Why?
|
| Lithium Carbonate | 16 | 2012 | 184 | 2.330 |
Why?
|
| Valproic Acid | 22 | 2012 | 445 | 2.290 |
Why?
|
| Piperazines | 11 | 2019 | 2488 | 1.410 |
Why?
|
| Psychotropic Drugs | 15 | 2018 | 894 | 1.390 |
Why?
|
| Psychiatric Status Rating Scales | 83 | 2021 | 6038 | 1.350 |
Why?
|
| Depressive Disorder, Major | 21 | 2023 | 4644 | 1.230 |
Why?
|
| Lithium | 23 | 2011 | 601 | 1.200 |
Why?
|
| Thiazoles | 7 | 2014 | 1483 | 1.190 |
Why?
|
| Anticonvulsants | 29 | 2010 | 1916 | 1.160 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 27 | 2019 | 1953 | 1.090 |
Why?
|
| Triazines | 12 | 2011 | 315 | 1.050 |
Why?
|
| Depressive Disorder | 37 | 2018 | 3748 | 0.940 |
Why?
|
| Double-Blind Method | 49 | 2023 | 12025 | 0.880 |
Why?
|
| Antidepressive Agents, Second-Generation | 5 | 2007 | 503 | 0.810 |
Why?
|
| Suicide, Attempted | 14 | 2011 | 1218 | 0.740 |
Why?
|
| Paroxetine | 4 | 2007 | 182 | 0.710 |
Why?
|
| Benzodiazepines | 18 | 2022 | 1101 | 0.700 |
Why?
|
| Drug Therapy, Combination | 42 | 2012 | 6489 | 0.690 |
Why?
|
| Quinolones | 4 | 2021 | 367 | 0.670 |
Why?
|
| Adult | 196 | 2023 | 214056 | 0.660 |
Why?
|
| Schizophrenic Psychology | 6 | 2010 | 1678 | 0.650 |
Why?
|
| Treatment Outcome | 82 | 2023 | 63115 | 0.640 |
Why?
|
| Risperidone | 6 | 2006 | 383 | 0.640 |
Why?
|
| Psychomotor Agitation | 5 | 2009 | 293 | 0.630 |
Why?
|
| Organic Anion Transporters, Sodium-Dependent | 3 | 2002 | 26 | 0.630 |
Why?
|
| H(+)-K(+)-Exchanging ATPase | 11 | 2001 | 36 | 0.630 |
Why?
|
| Receptor, Melatonin, MT1 | 1 | 2017 | 30 | 0.600 |
Why?
|
| Age of Onset | 18 | 2010 | 3270 | 0.580 |
Why?
|
| Seasonal Affective Disorder | 7 | 1999 | 50 | 0.580 |
Why?
|
| Receptor, Melatonin, MT2 | 1 | 2017 | 77 | 0.570 |
Why?
|
| Indenes | 1 | 2017 | 57 | 0.570 |
Why?
|
| Affect | 16 | 2017 | 1475 | 0.570 |
Why?
|
| Inositol | 3 | 2006 | 218 | 0.560 |
Why?
|
| Cognition Disorders | 7 | 2012 | 4043 | 0.550 |
Why?
|
| Lithium Compounds | 11 | 2011 | 225 | 0.540 |
Why?
|
| Psychotherapy | 11 | 2008 | 1643 | 0.530 |
Why?
|
| National Institute of Mental Health (U.S.) | 3 | 2011 | 107 | 0.500 |
Why?
|
| Phototherapy | 7 | 1999 | 377 | 0.500 |
Why?
|
| Symporters | 3 | 2002 | 361 | 0.500 |
Why?
|
| Humans | 279 | 2023 | 744376 | 0.490 |
Why?
|
| Female | 201 | 2021 | 380200 | 0.480 |
Why?
|
| Schizophrenia | 10 | 2012 | 6882 | 0.480 |
Why?
|
| Patient Care Management | 3 | 2006 | 306 | 0.480 |
Why?
|
| Male | 181 | 2021 | 350118 | 0.480 |
Why?
|
| Isoindoles | 1 | 2014 | 41 | 0.480 |
Why?
|
| Disease Management | 3 | 2014 | 2460 | 0.460 |
Why?
|
| Personality Inventory | 14 | 2013 | 1030 | 0.450 |
Why?
|
| Personality | 3 | 2013 | 552 | 0.440 |
Why?
|
| Suicide | 7 | 2013 | 1474 | 0.430 |
Why?
|
| Serotonin Antagonists | 2 | 2011 | 144 | 0.430 |
Why?
|
| Family Therapy | 4 | 2008 | 207 | 0.430 |
Why?
|
| Signal Detection, Psychological | 1 | 2012 | 85 | 0.430 |
Why?
|
| Psychotic Disorders | 10 | 2011 | 3046 | 0.420 |
Why?
|
| Mood Disorders | 5 | 2009 | 1106 | 0.420 |
Why?
|
| Bile Acids and Salts | 3 | 2002 | 368 | 0.410 |
Why?
|
| Bupropion | 3 | 2007 | 303 | 0.400 |
Why?
|
| Clonazepam | 9 | 1993 | 136 | 0.400 |
Why?
|
| Drug Administration Schedule | 17 | 2014 | 4933 | 0.400 |
Why?
|
| Polypharmacy | 1 | 2013 | 294 | 0.380 |
Why?
|
| Depression | 16 | 2022 | 7766 | 0.380 |
Why?
|
| Middle Aged | 109 | 2021 | 213388 | 0.370 |
Why?
|
| Cooperative Behavior | 2 | 2009 | 1504 | 0.370 |
Why?
|
| Proton Pump Inhibitors | 3 | 2000 | 526 | 0.360 |
Why?
|
| Cholinesterase Inhibitors | 3 | 2009 | 238 | 0.350 |
Why?
|
| Longitudinal Studies | 35 | 2013 | 13988 | 0.350 |
Why?
|
| Behavior Therapy | 6 | 2012 | 865 | 0.350 |
Why?
|
| Severity of Illness Index | 31 | 2014 | 15535 | 0.340 |
Why?
|
| Patient Participation | 3 | 2013 | 1457 | 0.340 |
Why?
|
| Comorbidity | 27 | 2017 | 10388 | 0.330 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2012 | 719 | 0.330 |
Why?
|
| Pirenzepine | 7 | 2003 | 115 | 0.330 |
Why?
|
| Mutagenesis, Site-Directed | 6 | 2002 | 1723 | 0.330 |
Why?
|
| Psychometrics | 8 | 2016 | 3002 | 0.330 |
Why?
|
| Enzyme Inhibitors | 4 | 2000 | 3799 | 0.320 |
Why?
|
| Adolescent | 57 | 2021 | 85784 | 0.320 |
Why?
|
| Patient Compliance | 10 | 2007 | 2685 | 0.320 |
Why?
|
| Social Perception | 1 | 2012 | 425 | 0.320 |
Why?
|
| Secondary Prevention | 14 | 2011 | 1530 | 0.320 |
Why?
|
| Basal Ganglia Diseases | 4 | 2012 | 149 | 0.310 |
Why?
|
| Irritable Mood | 3 | 2009 | 183 | 0.310 |
Why?
|
| Indans | 2 | 2006 | 96 | 0.300 |
Why?
|
| Community-Based Participatory Research | 1 | 2009 | 214 | 0.300 |
Why?
|
| Stomach | 7 | 2000 | 697 | 0.290 |
Why?
|
| Acute Disease | 12 | 2014 | 7147 | 0.290 |
Why?
|
| Placebos | 13 | 2014 | 1676 | 0.290 |
Why?
|
| Hyperandrogenism | 2 | 2006 | 38 | 0.290 |
Why?
|
| Combined Modality Therapy | 17 | 2017 | 8642 | 0.280 |
Why?
|
| Gastric Acid | 3 | 2000 | 104 | 0.280 |
Why?
|
| Periodicity | 3 | 2004 | 364 | 0.280 |
Why?
|
| Decision Trees | 4 | 2006 | 506 | 0.270 |
Why?
|
| Oligomenorrhea | 1 | 2006 | 45 | 0.270 |
Why?
|
| Mental Health Services | 5 | 2005 | 1643 | 0.270 |
Why?
|
| Role | 1 | 2006 | 175 | 0.270 |
Why?
|
| Magnetic Resonance Spectroscopy | 9 | 2009 | 3759 | 0.270 |
Why?
|
| Akathisia, Drug-Induced | 2 | 2014 | 67 | 0.260 |
Why?
|
| Panic Disorder | 10 | 2004 | 616 | 0.260 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2021 | 10943 | 0.260 |
Why?
|
| Cost of Illness | 6 | 2017 | 1860 | 0.260 |
Why?
|
| Carrier Proteins | 4 | 2010 | 5023 | 0.250 |
Why?
|
| Practice Guidelines as Topic | 9 | 2008 | 7281 | 0.240 |
Why?
|
| Body Weight | 5 | 2011 | 4671 | 0.240 |
Why?
|
| Community Health Services | 1 | 2009 | 650 | 0.240 |
Why?
|
| Dibenzothiazepines | 1 | 2004 | 103 | 0.240 |
Why?
|
| Membrane Glycoproteins | 3 | 2008 | 3771 | 0.230 |
Why?
|
| Neuropsychological Tests | 8 | 2010 | 6994 | 0.230 |
Why?
|
| Hydroxysteroid Dehydrogenases | 1 | 2002 | 29 | 0.220 |
Why?
|
| Thiazepines | 1 | 2002 | 30 | 0.220 |
Why?
|
| Panic | 6 | 1991 | 106 | 0.220 |
Why?
|
| Fructose | 2 | 2002 | 289 | 0.220 |
Why?
|
| Anxiety Disorders | 16 | 2006 | 2690 | 0.220 |
Why?
|
| Data Collection | 4 | 2006 | 3339 | 0.220 |
Why?
|
| Peptic Ulcer | 2 | 2000 | 223 | 0.210 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 4 | 2006 | 295 | 0.210 |
Why?
|
| Patient Selection | 3 | 2012 | 4216 | 0.210 |
Why?
|
| Gastric Mucosa | 3 | 2000 | 599 | 0.210 |
Why?
|
| Clinical Trials as Topic | 13 | 2008 | 7914 | 0.210 |
Why?
|
| Medication Adherence | 2 | 2013 | 2063 | 0.210 |
Why?
|
| Evidence-Based Practice | 1 | 2007 | 501 | 0.210 |
Why?
|
| Omeprazole | 3 | 2000 | 112 | 0.210 |
Why?
|
| Substance-Related Disorders | 10 | 2006 | 4257 | 0.210 |
Why?
|
| Randomized Controlled Trials as Topic | 13 | 2011 | 9957 | 0.210 |
Why?
|
| Haloperidol | 2 | 2009 | 397 | 0.210 |
Why?
|
| Amenorrhea | 1 | 2006 | 485 | 0.210 |
Why?
|
| Research Design | 6 | 2017 | 5986 | 0.200 |
Why?
|
| Minority Groups | 1 | 2009 | 1220 | 0.200 |
Why?
|
| Anger | 1 | 2004 | 402 | 0.200 |
Why?
|
| Disclosure | 1 | 2007 | 736 | 0.200 |
Why?
|
| Dopamine Agonists | 2 | 2021 | 355 | 0.200 |
Why?
|
| Parietal Cells, Gastric | 2 | 1992 | 47 | 0.200 |
Why?
|
| Serotonin Agents | 1 | 2021 | 29 | 0.200 |
Why?
|
| Isoenzymes | 3 | 2001 | 1728 | 0.200 |
Why?
|
| Drug Monitoring | 1 | 2007 | 956 | 0.200 |
Why?
|
| Protons | 4 | 2009 | 1127 | 0.190 |
Why?
|
| Brief Psychiatric Rating Scale | 3 | 2006 | 108 | 0.190 |
Why?
|
| Piperidines | 3 | 2006 | 1602 | 0.190 |
Why?
|
| Sick Role | 5 | 1996 | 237 | 0.190 |
Why?
|
| Violence | 2 | 2006 | 909 | 0.180 |
Why?
|
| Attitude | 1 | 2005 | 776 | 0.180 |
Why?
|
| Prospective Studies | 26 | 2016 | 53291 | 0.180 |
Why?
|
| Phosphatidylinositols | 1 | 2001 | 291 | 0.180 |
Why?
|
| Ileum | 1 | 2002 | 565 | 0.180 |
Why?
|
| Hospital Departments | 1 | 2000 | 137 | 0.180 |
Why?
|
| Epidemiologic Research Design | 1 | 2003 | 367 | 0.170 |
Why?
|
| Cohort Studies | 16 | 2011 | 40558 | 0.170 |
Why?
|
| Anti-Obesity Agents | 1 | 2002 | 217 | 0.170 |
Why?
|
| Awareness | 2 | 2001 | 640 | 0.170 |
Why?
|
| Follow-Up Studies | 23 | 2013 | 39052 | 0.170 |
Why?
|
| Interview, Psychological | 6 | 2012 | 812 | 0.170 |
Why?
|
| Electroconvulsive Therapy | 4 | 2001 | 477 | 0.160 |
Why?
|
| Surgery Department, Hospital | 1 | 2000 | 175 | 0.160 |
Why?
|
| Adenosine Triphosphatases | 6 | 1998 | 839 | 0.160 |
Why?
|
| Prevalence | 14 | 2010 | 15221 | 0.160 |
Why?
|
| Cyclothymic Disorder | 3 | 2009 | 41 | 0.160 |
Why?
|
| Sodium | 2 | 2002 | 1622 | 0.160 |
Why?
|
| Receptors, Cholecystokinin | 1 | 1997 | 18 | 0.160 |
Why?
|
| Weight Gain | 6 | 2017 | 2293 | 0.160 |
Why?
|
| Patient Education as Topic | 4 | 2007 | 2278 | 0.150 |
Why?
|
| Chronic Disease | 6 | 2017 | 9145 | 0.150 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2009 | 1121 | 0.150 |
Why?
|
| Administration, Sublingual | 1 | 2017 | 56 | 0.150 |
Why?
|
| Young Adult | 13 | 2021 | 56434 | 0.150 |
Why?
|
| Calcium Channels, L-Type | 2 | 2010 | 240 | 0.150 |
Why?
|
| Health Status Disparities | 1 | 2009 | 1796 | 0.150 |
Why?
|
| Ambulatory Care | 11 | 2008 | 2708 | 0.150 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 1998 | 141 | 0.150 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2006 | 1344 | 0.140 |
Why?
|
| Chlorides | 2 | 1990 | 667 | 0.140 |
Why?
|
| Imidazoles | 2 | 2000 | 1206 | 0.140 |
Why?
|
| Thyroxine | 1 | 2000 | 667 | 0.140 |
Why?
|
| Molecular Sequence Data | 11 | 2002 | 18111 | 0.140 |
Why?
|
| Thiophenes | 1 | 2021 | 589 | 0.140 |
Why?
|
| Drug Resistance | 6 | 2006 | 1608 | 0.140 |
Why?
|
| Amines | 1 | 1998 | 276 | 0.140 |
Why?
|
| Amino Acid Sequence | 9 | 2002 | 13814 | 0.140 |
Why?
|
| Mental Disorders | 5 | 2006 | 6600 | 0.140 |
Why?
|
| Administration, Oral | 3 | 2012 | 3914 | 0.130 |
Why?
|
| Demography | 5 | 2007 | 1656 | 0.130 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1995 | 42 | 0.130 |
Why?
|
| Sensitivity and Specificity | 5 | 2016 | 14723 | 0.130 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2010 | 8949 | 0.130 |
Why?
|
| Alprazolam | 7 | 1994 | 98 | 0.130 |
Why?
|
| Family | 2 | 2005 | 3147 | 0.130 |
Why?
|
| Kinetics | 7 | 2002 | 6476 | 0.130 |
Why?
|
| Interviews as Topic | 2 | 2013 | 2539 | 0.130 |
Why?
|
| Aged | 36 | 2021 | 163284 | 0.130 |
Why?
|
| Mental Processes | 1 | 2016 | 249 | 0.130 |
Why?
|
| Quaternary Ammonium Compounds | 3 | 2000 | 205 | 0.120 |
Why?
|
| Recurrence | 11 | 2011 | 8340 | 0.120 |
Why?
|
| Rabbits | 7 | 2000 | 4894 | 0.120 |
Why?
|
| Memory Disorders | 4 | 2005 | 1186 | 0.120 |
Why?
|
| Desipramine | 1 | 1994 | 184 | 0.120 |
Why?
|
| Climacteric | 1 | 1994 | 57 | 0.120 |
Why?
|
| Quality of Life | 14 | 2018 | 12803 | 0.120 |
Why?
|
| China | 2 | 2019 | 2245 | 0.120 |
Why?
|
| Health Education | 1 | 2001 | 1056 | 0.120 |
Why?
|
| Agoraphobia | 4 | 2004 | 179 | 0.120 |
Why?
|
| Tremor | 1 | 2014 | 175 | 0.120 |
Why?
|
| ROC Curve | 3 | 2019 | 3527 | 0.120 |
Why?
|
| Dyspepsia | 1 | 2014 | 116 | 0.120 |
Why?
|
| Physician-Patient Relations | 3 | 2013 | 3229 | 0.110 |
Why?
|
| Cerebral Cortex | 1 | 2010 | 5709 | 0.110 |
Why?
|
| Prefrontal Cortex | 3 | 2010 | 2147 | 0.110 |
Why?
|
| Protein Biosynthesis | 2 | 1998 | 2126 | 0.110 |
Why?
|
| Models, Psychological | 3 | 2008 | 811 | 0.110 |
Why?
|
| Risk Factors | 21 | 2011 | 72295 | 0.110 |
Why?
|
| Internal Medicine | 1 | 2000 | 1009 | 0.110 |
Why?
|
| Reproducibility of Results | 6 | 2016 | 19905 | 0.110 |
Why?
|
| Peptide Fragments | 2 | 2002 | 5096 | 0.110 |
Why?
|
| Cell Line | 8 | 2002 | 16000 | 0.110 |
Why?
|
| Verbal Learning | 2 | 2005 | 468 | 0.110 |
Why?
|
| Gastroesophageal Reflux | 1 | 2000 | 782 | 0.110 |
Why?
|
| Imipramine | 3 | 2001 | 97 | 0.110 |
Why?
|
| Cross-Sectional Studies | 14 | 2009 | 25041 | 0.110 |
Why?
|
| Registries | 2 | 2007 | 8091 | 0.110 |
Why?
|
| Outpatients | 3 | 2012 | 1487 | 0.110 |
Why?
|
| Inpatients | 2 | 2004 | 2518 | 0.110 |
Why?
|
| Stress, Physiological | 1 | 2000 | 1403 | 0.100 |
Why?
|
| Receptors, Muscarinic | 1 | 1992 | 156 | 0.100 |
Why?
|
| Logistic Models | 7 | 2013 | 13409 | 0.100 |
Why?
|
| Taurocholic Acid | 2 | 2002 | 43 | 0.100 |
Why?
|
| Kidney | 4 | 2001 | 7184 | 0.100 |
Why?
|
| Mesylates | 2 | 2002 | 36 | 0.100 |
Why?
|
| Perception | 1 | 2018 | 1198 | 0.100 |
Why?
|
| Calcium | 6 | 2000 | 5755 | 0.100 |
Why?
|
| Caregivers | 3 | 2008 | 2095 | 0.100 |
Why?
|
| Program Evaluation | 4 | 2009 | 2488 | 0.100 |
Why?
|
| Vomiting | 1 | 2014 | 637 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 1 | 4 | 1994 | 3338 | 0.100 |
Why?
|
| Dominance, Cerebral | 2 | 2010 | 635 | 0.100 |
Why?
|
| Anti-Ulcer Agents | 2 | 2000 | 119 | 0.100 |
Why?
|
| Gastrointestinal Diseases | 1 | 2000 | 1170 | 0.100 |
Why?
|
| Carbamazepine | 5 | 2001 | 229 | 0.100 |
Why?
|
| Obesity | 10 | 2006 | 12745 | 0.100 |
Why?
|
| Alcoholism | 3 | 2010 | 1906 | 0.100 |
Why?
|
| Growth Hormone | 1 | 1993 | 705 | 0.100 |
Why?
|
| Child Behavior Disorders | 2 | 2006 | 807 | 0.100 |
Why?
|
| United States | 15 | 2011 | 69869 | 0.100 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 4 | 2006 | 3658 | 0.090 |
Why?
|
| Patient Care Planning | 3 | 2005 | 921 | 0.090 |
Why?
|
| Attention | 3 | 2010 | 2397 | 0.090 |
Why?
|
| Pilot Projects | 8 | 2007 | 8319 | 0.090 |
Why?
|
| Brain | 9 | 2009 | 26386 | 0.090 |
Why?
|
| Premenstrual Syndrome | 1 | 2011 | 109 | 0.090 |
Why?
|
| Manganese Compounds | 1 | 1990 | 27 | 0.090 |
Why?
|
| Fear | 3 | 1987 | 1440 | 0.090 |
Why?
|
| Clinical Protocols | 4 | 2007 | 1462 | 0.090 |
Why?
|
| Circadian Rhythm Signaling Peptides and Proteins | 1 | 2009 | 30 | 0.090 |
Why?
|
| Reference Values | 4 | 2010 | 4982 | 0.090 |
Why?
|
| Cell Compartmentation | 1 | 1990 | 402 | 0.090 |
Why?
|
| Dihydroergotoxine | 1 | 1989 | 21 | 0.090 |
Why?
|
| Receptors, Pituitary Hormone | 2 | 1999 | 29 | 0.090 |
Why?
|
| Cross-Cultural Comparison | 2 | 2010 | 651 | 0.090 |
Why?
|
| Time Factors | 14 | 2011 | 40077 | 0.090 |
Why?
|
| Patient Satisfaction | 2 | 2013 | 3395 | 0.090 |
Why?
|
| Advisory Committees | 2 | 2013 | 775 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2010 | 417 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2002 | 3773 | 0.080 |
Why?
|
| Incidence | 5 | 2006 | 20950 | 0.080 |
Why?
|
| Translating | 1 | 2010 | 144 | 0.080 |
Why?
|
| Euphoria | 1 | 2009 | 67 | 0.080 |
Why?
|
| Adaptation, Psychological | 7 | 2008 | 2575 | 0.080 |
Why?
|
| Galantamine | 1 | 2009 | 32 | 0.080 |
Why?
|
| Patient Dropouts | 3 | 2007 | 421 | 0.080 |
Why?
|
| Wound Healing | 1 | 2000 | 2785 | 0.080 |
Why?
|
| Psychotherapy, Group | 3 | 1998 | 406 | 0.080 |
Why?
|
| Arousal | 2 | 1993 | 1164 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2010 | 380 | 0.080 |
Why?
|
| Retrospective Studies | 19 | 2019 | 77459 | 0.080 |
Why?
|
| Ankyrins | 1 | 2008 | 128 | 0.080 |
Why?
|
| Internet | 4 | 2018 | 3064 | 0.080 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 1991 | 434 | 0.080 |
Why?
|
| Personality Disorders | 2 | 1992 | 713 | 0.080 |
Why?
|
| Survival Analysis | 7 | 2010 | 10252 | 0.080 |
Why?
|
| Myosin Type V | 1 | 2008 | 34 | 0.080 |
Why?
|
| Facial Expression | 1 | 2012 | 508 | 0.080 |
Why?
|
| Phobic Disorders | 4 | 1994 | 439 | 0.080 |
Why?
|
| Neuroleptic Malignant Syndrome | 1 | 1988 | 71 | 0.080 |
Why?
|
| Germany | 1 | 2010 | 862 | 0.080 |
Why?
|
| Risk | 4 | 2010 | 9688 | 0.080 |
Why?
|
| Sex Distribution | 2 | 2003 | 2297 | 0.080 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2018 | 3020 | 0.080 |
Why?
|
| Sulpiride | 1 | 2007 | 17 | 0.070 |
Why?
|
| Pancreas | 3 | 1991 | 1687 | 0.070 |
Why?
|
| Choline | 3 | 2009 | 493 | 0.070 |
Why?
|
| Diagnosis, Differential | 7 | 2009 | 12961 | 0.070 |
Why?
|
| Brain Mapping | 5 | 2010 | 6670 | 0.070 |
Why?
|
| Obsessive-Compulsive Disorder | 3 | 2005 | 1444 | 0.070 |
Why?
|
| Yohimbine | 1 | 1986 | 62 | 0.070 |
Why?
|
| Activities of Daily Living | 2 | 2006 | 2418 | 0.070 |
Why?
|
| Amnesia | 1 | 1989 | 248 | 0.070 |
Why?
|
| Glycosylation | 2 | 2002 | 1128 | 0.070 |
Why?
|
| Sex Factors | 6 | 2008 | 10400 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2010 | 15520 | 0.070 |
Why?
|
| Hospitals, Psychiatric | 1 | 1988 | 332 | 0.070 |
Why?
|
| Liver | 1 | 2002 | 7475 | 0.070 |
Why?
|
| Blood Glucose | 4 | 2004 | 6254 | 0.070 |
Why?
|
| Psychiatry | 1 | 1999 | 1695 | 0.070 |
Why?
|
| Myosin Heavy Chains | 1 | 2008 | 414 | 0.070 |
Why?
|
| Killer Cells, Natural | 1 | 1995 | 2133 | 0.070 |
Why?
|
| Binding Sites | 3 | 2000 | 6111 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2010 | 17445 | 0.070 |
Why?
|
| Adjuvants, Immunologic | 1 | 2011 | 1000 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2010 | 35424 | 0.070 |
Why?
|
| Parietal Lobe | 2 | 2010 | 838 | 0.070 |
Why?
|
| Potassium | 4 | 2001 | 1336 | 0.070 |
Why?
|
| Hydrocortisone | 1 | 1993 | 1826 | 0.070 |
Why?
|
| Genetic Vectors | 3 | 2002 | 3424 | 0.070 |
Why?
|
| Age Factors | 5 | 2009 | 18373 | 0.070 |
Why?
|
| Nucleoside-Triphosphatase | 1 | 2005 | 19 | 0.070 |
Why?
|
| Affective Symptoms | 1 | 2008 | 407 | 0.070 |
Why?
|
| Binding, Competitive | 3 | 2002 | 1157 | 0.070 |
Why?
|
| Psychotherapy, Brief | 1 | 2006 | 114 | 0.060 |
Why?
|
| September 11 Terrorist Attacks | 1 | 2006 | 113 | 0.060 |
Why?
|
| Metabolism | 1 | 2006 | 196 | 0.060 |
Why?
|
| Microscopy, Confocal | 2 | 2002 | 1970 | 0.060 |
Why?
|
| Frontal Lobe | 2 | 2010 | 1406 | 0.060 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2011 | 1004 | 0.060 |
Why?
|
| Decision Making | 2 | 2018 | 3888 | 0.060 |
Why?
|
| Menstruation Disturbances | 1 | 2006 | 148 | 0.060 |
Why?
|
| Linkage Disequilibrium | 1 | 2010 | 1997 | 0.060 |
Why?
|
| Utilization Review | 1 | 2006 | 392 | 0.060 |
Why?
|
| Metabolic Diseases | 1 | 2011 | 658 | 0.060 |
Why?
|
| Focus Groups | 1 | 2009 | 1321 | 0.060 |
Why?
|
| Enzyme Activation | 3 | 2000 | 3702 | 0.060 |
Why?
|
| Sleep | 3 | 2011 | 4623 | 0.060 |
Why?
|
| Rats | 10 | 2002 | 24252 | 0.060 |
Why?
|
| Ion Channels | 1 | 1989 | 1056 | 0.060 |
Why?
|
| Executive Function | 2 | 2010 | 1364 | 0.060 |
Why?
|
| Emergency Services, Psychiatric | 2 | 2003 | 68 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 3 | 2005 | 1677 | 0.060 |
Why?
|
| Fluoxetine | 2 | 2003 | 749 | 0.060 |
Why?
|
| Nonverbal Communication | 1 | 2004 | 63 | 0.060 |
Why?
|
| Lithium Chloride | 2 | 2011 | 87 | 0.060 |
Why?
|
| Self Concept | 1 | 2010 | 1025 | 0.060 |
Why?
|
| Personal Autonomy | 1 | 2006 | 298 | 0.060 |
Why?
|
| Prolactin | 1 | 2006 | 669 | 0.060 |
Why?
|
| Cell Membrane | 4 | 2000 | 3749 | 0.060 |
Why?
|
| Aggression | 2 | 2006 | 753 | 0.060 |
Why?
|
| Drug Utilization | 2 | 2009 | 1183 | 0.060 |
Why?
|
| Vitamin B Complex | 1 | 2006 | 288 | 0.060 |
Why?
|
| User-Computer Interface | 1 | 2010 | 1431 | 0.060 |
Why?
|
| Self Report | 3 | 2018 | 3557 | 0.060 |
Why?
|
| Case-Control Studies | 4 | 2010 | 21747 | 0.060 |
Why?
|
| Memory | 2 | 2010 | 2174 | 0.060 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2005 | 322 | 0.050 |
Why?
|
| Regression Analysis | 5 | 2019 | 6459 | 0.050 |
Why?
|
| Life Change Events | 4 | 2006 | 938 | 0.050 |
Why?
|
| Attitude to Health | 3 | 2010 | 2052 | 0.050 |
Why?
|
| Biological Transport, Active | 1 | 2002 | 349 | 0.050 |
Why?
|
| Social Support | 3 | 2008 | 2118 | 0.050 |
Why?
|
| Cations, Monovalent | 2 | 2000 | 25 | 0.050 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2006 | 370 | 0.050 |
Why?
|
| Anti-Anxiety Agents | 2 | 2004 | 390 | 0.050 |
Why?
|
| Memory, Short-Term | 1 | 2008 | 977 | 0.050 |
Why?
|
| Threonine | 1 | 2002 | 279 | 0.050 |
Why?
|
| Health Status | 4 | 2008 | 4033 | 0.050 |
Why?
|
| Ethics | 1 | 2002 | 94 | 0.050 |
Why?
|
| Terminology as Topic | 1 | 2009 | 1547 | 0.050 |
Why?
|
| Critical Pathways | 1 | 2006 | 476 | 0.050 |
Why?
|
| Emotions | 1 | 1993 | 2658 | 0.050 |
Why?
|
| Animals | 20 | 2002 | 168770 | 0.050 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2001 | 33 | 0.050 |
Why?
|
| Monitoring, Physiologic | 1 | 2009 | 1739 | 0.050 |
Why?
|
| Reproduction | 1 | 2006 | 668 | 0.050 |
Why?
|
| Electrocardiography | 2 | 2006 | 6442 | 0.050 |
Why?
|
| Long-Term Care | 3 | 2005 | 607 | 0.050 |
Why?
|
| Clozapine | 2 | 2005 | 498 | 0.050 |
Why?
|
| Antiparkinson Agents | 1 | 2002 | 184 | 0.050 |
Why?
|
| Functional Laterality | 1 | 2008 | 2290 | 0.050 |
Why?
|
| Valine | 1 | 2002 | 413 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 2 | 2010 | 2716 | 0.050 |
Why?
|
| Atropine | 2 | 1992 | 244 | 0.050 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2002 | 407 | 0.050 |
Why?
|
| Acid-Base Equilibrium | 1 | 2001 | 185 | 0.050 |
Why?
|
| Sulfhydryl Reagents | 1 | 2000 | 32 | 0.050 |
Why?
|
| Family Health | 1 | 2006 | 1281 | 0.050 |
Why?
|
| Genome | 1 | 2009 | 1807 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2009 | 2682 | 0.050 |
Why?
|
| Personality Assessment | 4 | 2010 | 647 | 0.050 |
Why?
|
| Consensus | 4 | 2013 | 2960 | 0.050 |
Why?
|
| Half-Life | 1 | 2001 | 661 | 0.050 |
Why?
|
| Enterochromaffin-like Cells | 1 | 1999 | 4 | 0.050 |
Why?
|
| Dinoprost | 1 | 2000 | 138 | 0.050 |
Why?
|
| Serotonin | 1 | 2005 | 1017 | 0.050 |
Why?
|
| Reproductive Techniques | 1 | 2000 | 42 | 0.050 |
Why?
|
| Prognosis | 6 | 2009 | 29060 | 0.040 |
Why?
|
| CHO Cells | 1 | 2002 | 1409 | 0.040 |
Why?
|
| Austria | 1 | 2000 | 203 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2008 | 1988 | 0.040 |
Why?
|
| Base Sequence | 4 | 1998 | 12797 | 0.040 |
Why?
|
| Drug Eruptions | 1 | 2002 | 297 | 0.040 |
Why?
|
| Diet, Reducing | 2 | 1985 | 462 | 0.040 |
Why?
|
| DNA, Complementary | 3 | 1998 | 2050 | 0.040 |
Why?
|
| Observer Variation | 1 | 2005 | 2593 | 0.040 |
Why?
|
| Enterochromaffin Cells | 1 | 1998 | 14 | 0.040 |
Why?
|
| Luminescent Proteins | 1 | 2002 | 853 | 0.040 |
Why?
|
| Blotting, Southern | 3 | 1998 | 803 | 0.040 |
Why?
|
| Serotonin 5-HT1 Receptor Agonists | 1 | 2019 | 43 | 0.040 |
Why?
|
| Environment | 1 | 2005 | 1123 | 0.040 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2001 | 434 | 0.040 |
Why?
|
| Fallopian Tubes | 1 | 2000 | 182 | 0.040 |
Why?
|
| Receptor, Serotonin, 5-HT1A | 1 | 2019 | 53 | 0.040 |
Why?
|
| Serine | 1 | 2002 | 826 | 0.040 |
Why?
|
| Cricetinae | 1 | 2002 | 2475 | 0.040 |
Why?
|
| United States Agency for Healthcare Research and Quality | 1 | 1999 | 92 | 0.040 |
Why?
|
| Benzimidazoles | 1 | 1984 | 850 | 0.040 |
Why?
|
| Citalopram | 1 | 2001 | 403 | 0.040 |
Why?
|
| Blotting, Western | 4 | 2000 | 5181 | 0.040 |
Why?
|
| Rubidium | 1 | 1998 | 133 | 0.040 |
Why?
|
| Molecular Conformation | 1 | 2000 | 562 | 0.040 |
Why?
|
| Hospitals, Rural | 1 | 2000 | 172 | 0.040 |
Why?
|
| Receptors, Dopamine D3 | 1 | 2019 | 110 | 0.040 |
Why?
|
| Child | 9 | 2009 | 77708 | 0.040 |
Why?
|
| Pregnancy, Ectopic | 1 | 2000 | 141 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2006 | 5077 | 0.040 |
Why?
|
| Gene Frequency | 3 | 2010 | 3587 | 0.040 |
Why?
|
| Sequence Alignment | 1 | 2002 | 2256 | 0.040 |
Why?
|
| Office Visits | 1 | 2002 | 598 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2000 | 499 | 0.040 |
Why?
|
| Cysteine | 1 | 2002 | 873 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2005 | 1405 | 0.040 |
Why?
|
| Receptor, Cholecystokinin A | 1 | 1997 | 13 | 0.040 |
Why?
|
| Genotype | 5 | 2010 | 12952 | 0.040 |
Why?
|
| Overweight | 2 | 2006 | 2371 | 0.040 |
Why?
|
| Helicobacter | 1 | 1998 | 112 | 0.040 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 2 | 1998 | 494 | 0.040 |
Why?
|
| Biological Transport | 2 | 2000 | 2120 | 0.040 |
Why?
|
| Music Therapy | 1 | 2018 | 102 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2009 | 3743 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 1992 | 13035 | 0.040 |
Why?
|
| Interpersonal Relations | 2 | 2018 | 1425 | 0.040 |
Why?
|
| Operon | 1 | 1998 | 363 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1997 | 1801 | 0.040 |
Why?
|
| Age Distribution | 1 | 2003 | 2902 | 0.040 |
Why?
|
| Chromosome Mapping | 3 | 2010 | 4740 | 0.040 |
Why?
|
| Triamcinolone | 1 | 1996 | 68 | 0.040 |
Why?
|
| Protein Structure, Secondary | 1 | 2000 | 1247 | 0.040 |
Why?
|
| Bacterial Proteins | 2 | 2002 | 3854 | 0.040 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2019 | 475 | 0.040 |
Why?
|
| Acetates | 1 | 1998 | 311 | 0.030 |
Why?
|
| Protein Transport | 1 | 2002 | 1988 | 0.030 |
Why?
|
| Hypokalemia | 1 | 1997 | 153 | 0.030 |
Why?
|
| Diabetic Ketoacidosis | 1 | 1999 | 245 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 2006 | 2795 | 0.030 |
Why?
|
| Algorithms | 4 | 2005 | 13882 | 0.030 |
Why?
|
| Genome-Wide Association Study | 3 | 2010 | 12262 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2006 | 2759 | 0.030 |
Why?
|
| Structure-Activity Relationship | 2 | 2000 | 3130 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2000 | 1899 | 0.030 |
Why?
|
| Health Services Research | 1 | 2003 | 1836 | 0.030 |
Why?
|
| Nootropic Agents | 1 | 1996 | 160 | 0.030 |
Why?
|
| Neurologic Examination | 2 | 1996 | 931 | 0.030 |
Why?
|
| Models, Chemical | 1 | 1997 | 626 | 0.030 |
Why?
|
| Ovary | 1 | 2000 | 981 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2002 | 3848 | 0.030 |
Why?
|
| Disease Progression | 3 | 2010 | 13285 | 0.030 |
Why?
|
| Transfection | 2 | 2000 | 5895 | 0.030 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 3047 | 0.030 |
Why?
|
| Disease Susceptibility | 2 | 2000 | 1782 | 0.030 |
Why?
|
| Genome, Human | 1 | 2008 | 4420 | 0.030 |
Why?
|
| DNA | 2 | 2008 | 7294 | 0.030 |
Why?
|
| Evidence-Based Medicine | 2 | 2005 | 3610 | 0.030 |
Why?
|
| Treatment Refusal | 1 | 1998 | 421 | 0.030 |
Why?
|
| Fluorescent Dyes | 3 | 1991 | 1917 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 1999 | 875 | 0.030 |
Why?
|
| Body Mass Index | 4 | 2006 | 12720 | 0.030 |
Why?
|
| Propranolol | 1 | 1996 | 502 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2008 | 3209 | 0.030 |
Why?
|
| Case Management | 1 | 1996 | 286 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 1999 | 1117 | 0.030 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 2 | 2006 | 304 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 4328 | 0.030 |
Why?
|
| Sincalide | 2 | 1990 | 16 | 0.030 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2006 | 4266 | 0.030 |
Why?
|
| Colitis, Ulcerative | 2 | 1996 | 1911 | 0.030 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 2 | 1990 | 102 | 0.030 |
Why?
|
| Antibodies | 1 | 2001 | 2460 | 0.030 |
Why?
|
| N-Methylscopolamine | 1 | 1992 | 4 | 0.030 |
Why?
|
| Scopolamine Derivatives | 1 | 1992 | 23 | 0.030 |
Why?
|
| Hippocampus | 1 | 2005 | 3675 | 0.030 |
Why?
|
| Crohn Disease | 2 | 1996 | 2304 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 1996 | 547 | 0.030 |
Why?
|
| Texas | 2 | 2005 | 391 | 0.030 |
Why?
|
| Smoking | 1 | 2009 | 8987 | 0.030 |
Why?
|
| Dogs | 1 | 1997 | 3912 | 0.030 |
Why?
|
| Alzheimer Disease | 2 | 2006 | 8038 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 1999 | 1359 | 0.030 |
Why?
|
| Stress, Psychological | 3 | 2008 | 4244 | 0.030 |
Why?
|
| Hydroquinones | 1 | 1991 | 36 | 0.030 |
Why?
|
| Complementary Therapies | 1 | 1996 | 486 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 1995 | 968 | 0.030 |
Why?
|
| Lung Volume Measurements | 1 | 1993 | 378 | 0.030 |
Why?
|
| Seasons | 1 | 1997 | 1493 | 0.030 |
Why?
|
| Pregnancy | 3 | 2006 | 29144 | 0.030 |
Why?
|
| Epilepsy | 1 | 1987 | 3310 | 0.030 |
Why?
|
| Semantics | 2 | 2005 | 585 | 0.020 |
Why?
|
| Dementia | 1 | 2006 | 2518 | 0.020 |
Why?
|
| Terpenes | 1 | 1991 | 98 | 0.020 |
Why?
|
| Epilepsies, Partial | 1 | 1995 | 436 | 0.020 |
Why?
|
| Aminoquinolines | 1 | 1991 | 109 | 0.020 |
Why?
|
| Norepinephrine | 1 | 1993 | 909 | 0.020 |
Why?
|
| Thoracotomy | 1 | 1993 | 363 | 0.020 |
Why?
|
| Delphi Technique | 1 | 2013 | 779 | 0.020 |
Why?
|
| Manganese | 2 | 1991 | 408 | 0.020 |
Why?
|
| Thiothixene | 1 | 1990 | 3 | 0.020 |
Why?
|
| Digitonin | 1 | 1990 | 27 | 0.020 |
Why?
|
| Aspartic Acid | 2 | 2009 | 576 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2001 | 11366 | 0.020 |
Why?
|
| Adrenomedullin | 1 | 2010 | 87 | 0.020 |
Why?
|
| Circadian Rhythm | 2 | 2009 | 2624 | 0.020 |
Why?
|
| Hospitalization | 3 | 2005 | 10259 | 0.020 |
Why?
|
| Fura-2 | 1 | 1990 | 109 | 0.020 |
Why?
|
| Epinephrine | 1 | 1993 | 792 | 0.020 |
Why?
|
| Oligonucleotide Probes | 1 | 1990 | 427 | 0.020 |
Why?
|
| Egtazic Acid | 1 | 1990 | 173 | 0.020 |
Why?
|
| Necturus | 1 | 1989 | 14 | 0.020 |
Why?
|
| Cloning, Molecular | 2 | 1998 | 4320 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 1990 | 878 | 0.020 |
Why?
|
| Remission Induction | 2 | 2006 | 2386 | 0.020 |
Why?
|
| Health Surveys | 1 | 2000 | 4036 | 0.020 |
Why?
|
| Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide | 2 | 1999 | 12 | 0.020 |
Why?
|
| Bucladesine | 1 | 1989 | 121 | 0.020 |
Why?
|
| Brain Chemistry | 1 | 1993 | 982 | 0.020 |
Why?
|
| Carbachol | 1 | 1990 | 226 | 0.020 |
Why?
|
| Microsomes | 3 | 1998 | 257 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 15078 | 0.020 |
Why?
|
| Social Behavior | 2 | 2007 | 1127 | 0.020 |
Why?
|
| Benzofurans | 1 | 1990 | 140 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2010 | 6366 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1990 | 1085 | 0.020 |
Why?
|
| Guideline Adherence | 2 | 2010 | 2265 | 0.020 |
Why?
|
| Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I | 2 | 1999 | 52 | 0.020 |
Why?
|
| Doxepin | 2 | 1985 | 16 | 0.020 |
Why?
|
| Empathy | 1 | 2013 | 474 | 0.020 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1993 | 632 | 0.020 |
Why?
|
| Dangerous Behavior | 1 | 1988 | 66 | 0.020 |
Why?
|
| Proportional Hazards Models | 3 | 2011 | 12356 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2011 | 6539 | 0.020 |
Why?
|
| Societies, Scientific | 1 | 2009 | 220 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1990 | 2556 | 0.020 |
Why?
|
| Mental Recall | 2 | 2005 | 1206 | 0.020 |
Why?
|
| Triazolam | 1 | 1987 | 16 | 0.020 |
Why?
|
| Microelectrodes | 1 | 1989 | 303 | 0.020 |
Why?
|
| Commitment of Mentally Ill | 1 | 1988 | 94 | 0.020 |
Why?
|
| Chlorpromazine | 1 | 1988 | 111 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 2009 | 321 | 0.020 |
Why?
|
| Alleles | 2 | 2010 | 6933 | 0.020 |
Why?
|
| Phenotype | 3 | 2010 | 16367 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2009 | 374 | 0.020 |
Why?
|
| 3T3 Cells | 2 | 2000 | 1101 | 0.020 |
Why?
|
| Macromolecular Substances | 1 | 1990 | 1454 | 0.020 |
Why?
|
| Defense Mechanisms | 1 | 2008 | 178 | 0.020 |
Why?
|
| Mentally Ill Persons | 1 | 1988 | 126 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2008 | 287 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 1995 | 20823 | 0.020 |
Why?
|
| Tryptophan | 1 | 1989 | 478 | 0.020 |
Why?
|
| Gene Library | 1 | 1990 | 1074 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 1997 | 2732 | 0.020 |
Why?
|
| Anxiety | 3 | 1997 | 4296 | 0.020 |
Why?
|
| Receptors, AMPA | 1 | 2009 | 332 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2010 | 1005 | 0.020 |
Why?
|
| Psychophysiologic Disorders | 1 | 1989 | 228 | 0.020 |
Why?
|
| Thyroid Hormones | 1 | 1989 | 390 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 1996 | 2108 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2008 | 373 | 0.020 |
Why?
|
| Signal Transduction | 1 | 1990 | 23406 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2000 | 3529 | 0.020 |
Why?
|
| Enuresis | 1 | 2006 | 47 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2008 | 462 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2006 | 23336 | 0.020 |
Why?
|
| Temporal Lobe | 2 | 2001 | 1670 | 0.020 |
Why?
|
| Colon | 1 | 1995 | 1772 | 0.020 |
Why?
|
| Vision Disorders | 1 | 1994 | 1058 | 0.020 |
Why?
|
| Spectrum Analysis | 1 | 2009 | 454 | 0.020 |
Why?
|
| Neural Pathways | 1 | 1997 | 2973 | 0.020 |
Why?
|
| Vaginal Diseases | 1 | 1987 | 102 | 0.020 |
Why?
|
| Hirsutism | 1 | 2006 | 69 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 1995 | 6171 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2000 | 8300 | 0.020 |
Why?
|
| Cytosol | 1 | 1990 | 901 | 0.020 |
Why?
|
| Social Adjustment | 1 | 1989 | 631 | 0.020 |
Why?
|
| Hand Deformities, Congenital | 1 | 1987 | 146 | 0.020 |
Why?
|
| Uterine Diseases | 1 | 1987 | 135 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 1989 | 1137 | 0.020 |
Why?
|
| Pneumonectomy | 1 | 1993 | 1094 | 0.020 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1986 | 246 | 0.020 |
Why?
|
| Glutamine | 1 | 2009 | 579 | 0.020 |
Why?
|
| Wheat Germ Agglutinins | 2 | 1998 | 47 | 0.020 |
Why?
|
| Protein Conformation | 2 | 1990 | 4010 | 0.020 |
Why?
|
| Epithelium | 1 | 1990 | 1679 | 0.020 |
Why?
|
| Telecommunications | 1 | 2005 | 80 | 0.020 |
Why?
|
| Safety | 1 | 2010 | 1186 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 2887 | 0.020 |
Why?
|
| Postmenopause | 1 | 1994 | 2460 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2010 | 2421 | 0.020 |
Why?
|
| Limbic System | 1 | 1987 | 426 | 0.020 |
Why?
|
| Pulse | 1 | 2004 | 229 | 0.020 |
Why?
|
| Metabolome | 1 | 2011 | 895 | 0.020 |
Why?
|
| Wechsler Scales | 1 | 2005 | 260 | 0.020 |
Why?
|
| Conduct Disorder | 1 | 2006 | 241 | 0.020 |
Why?
|
| Home Care Services | 1 | 1991 | 606 | 0.020 |
Why?
|
| Forced Expiratory Volume | 1 | 2009 | 1745 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2010 | 1115 | 0.020 |
Why?
|
| Fingers | 1 | 1987 | 513 | 0.020 |
Why?
|
| Aged, 80 and over | 3 | 2009 | 57776 | 0.020 |
Why?
|
| California | 1 | 2008 | 1402 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 2 | 2005 | 2212 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 1993 | 1199 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1999 | 6542 | 0.010 |
Why?
|
| Medical History Taking | 1 | 2008 | 784 | 0.010 |
Why?
|
| Prejudice | 1 | 2008 | 570 | 0.010 |
Why?
|
| Employment | 1 | 2010 | 1132 | 0.010 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 1987 | 403 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 1998 | 2839 | 0.010 |
Why?
|
| Brain Diseases | 1 | 1993 | 1563 | 0.010 |
Why?
|
| Child, Preschool | 3 | 2006 | 41005 | 0.010 |
Why?
|
| Glutamic Acid | 1 | 2009 | 1169 | 0.010 |
Why?
|
| Child Abuse | 1 | 1992 | 1030 | 0.010 |
Why?
|
| Menarche | 1 | 2006 | 516 | 0.010 |
Why?
|
| Social Environment | 1 | 2008 | 1023 | 0.010 |
Why?
|
| Mass Media | 1 | 2006 | 305 | 0.010 |
Why?
|
| Electroencephalography | 2 | 1995 | 6150 | 0.010 |
Why?
|
| Self Care | 1 | 2008 | 786 | 0.010 |
Why?
|
| Self-Help Groups | 1 | 2004 | 190 | 0.010 |
Why?
|
| Databases, Genetic | 1 | 2009 | 1783 | 0.010 |
Why?
|
| Psychopathology | 1 | 2005 | 409 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 1987 | 1150 | 0.010 |
Why?
|
| Menstrual Cycle | 1 | 2006 | 551 | 0.010 |
Why?
|
| Time | 1 | 2004 | 542 | 0.010 |
Why?
|
| Personality Development | 2 | 1994 | 245 | 0.010 |
Why?
|
| Reaction Time | 1 | 2008 | 2098 | 0.010 |
Why?
|
| Episode of Care | 1 | 2002 | 126 | 0.010 |
Why?
|
| Psychological Tests | 1 | 2004 | 651 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 1997 | 1107 | 0.010 |
Why?
|
| Hypnotics and Sedatives | 1 | 2009 | 1162 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 1999 | 4751 | 0.010 |
Why?
|
| Adolescent Psychiatry | 1 | 2003 | 148 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2008 | 2634 | 0.010 |
Why?
|
| Phosphates | 1 | 2005 | 785 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 2006 | 1364 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2008 | 2715 | 0.010 |
Why?
|
| Receptors, Prostaglandin E, EP1 Subtype | 1 | 2000 | 9 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 2002 | 376 | 0.010 |
Why?
|
| Receptors, Epoprostenol | 1 | 2000 | 12 | 0.010 |
Why?
|
| Receptors, Thromboxane | 1 | 2000 | 31 | 0.010 |
Why?
|
| Receptors, Prostaglandin E, EP3 Subtype | 1 | 2000 | 23 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 1999 | 5749 | 0.010 |
Why?
|
| Receptors, Prostaglandin E, EP2 Subtype | 1 | 2000 | 40 | 0.010 |
Why?
|
| Prostaglandins F, Synthetic | 1 | 2000 | 32 | 0.010 |
Why?
|
| Receptors, Prostaglandin | 1 | 2000 | 57 | 0.010 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 1 | 2000 | 41 | 0.010 |
Why?
|
| Personal Satisfaction | 1 | 2005 | 643 | 0.010 |
Why?
|
| Receptors, Prostaglandin E | 1 | 2000 | 56 | 0.010 |
Why?
|
| Mice | 3 | 2002 | 81202 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2006 | 2618 | 0.010 |
Why?
|
| Prostaglandin D2 | 1 | 2000 | 122 | 0.010 |
Why?
|
| Menotropins | 1 | 2000 | 45 | 0.010 |
Why?
|
| Swine | 1 | 1990 | 5918 | 0.010 |
Why?
|
| Child Psychiatry | 1 | 2003 | 220 | 0.010 |
Why?
|
| Radioligand Assay | 1 | 2000 | 374 | 0.010 |
Why?
|
| Phosphorus | 1 | 2001 | 338 | 0.010 |
Why?
|
| DNA, Recombinant | 1 | 2000 | 476 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2006 | 2373 | 0.010 |
Why?
|
| Cues | 1 | 2005 | 875 | 0.010 |
Why?
|
| Histamine Release | 1 | 1999 | 142 | 0.010 |
Why?
|
| Socioeconomic Factors | 2 | 2009 | 7785 | 0.010 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2006 | 1206 | 0.010 |
Why?
|
| Benzothiazoles | 1 | 2000 | 248 | 0.010 |
Why?
|
| Catalysis | 2 | 1991 | 762 | 0.010 |
Why?
|
| Receptors, Vasoactive Intestinal Polypeptide, Type I | 1 | 1998 | 4 | 0.010 |
Why?
|
| Receptors, Vasoactive Intestinal Peptide, Type II | 1 | 1998 | 6 | 0.010 |
Why?
|
| Canada | 1 | 2005 | 2065 | 0.010 |
Why?
|
| Microscopy, Video | 1 | 1999 | 245 | 0.010 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2002 | 281 | 0.010 |
Why?
|
| Drug Approval | 1 | 2005 | 742 | 0.010 |
Why?
|
| Pituitary Adenylate Cyclase-Activating Polypeptide | 1 | 1999 | 102 | 0.010 |
Why?
|
| Cats | 1 | 2000 | 1000 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2008 | 3420 | 0.010 |
Why?
|
| Manuals as Topic | 1 | 1998 | 98 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 3508 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 2000 | 1386 | 0.010 |
Why?
|
| Spectrometry, Fluorescence | 2 | 1990 | 688 | 0.010 |
Why?
|
| COS Cells | 1 | 2000 | 1161 | 0.010 |
Why?
|
| Program Development | 1 | 2004 | 1316 | 0.010 |
Why?
|
| Peptides | 1 | 1990 | 4410 | 0.010 |
Why?
|
| Placebo Effect | 1 | 2002 | 502 | 0.010 |
Why?
|
| Embryo Implantation | 1 | 2000 | 272 | 0.010 |
Why?
|
| United States Food and Drug Administration | 1 | 2005 | 1584 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2013 | 4369 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 1996 | 25628 | 0.010 |
Why?
|
| Trypsin | 1 | 1998 | 511 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2010 | 4464 | 0.010 |
Why?
|
| Telephone | 1 | 2000 | 617 | 0.010 |
Why?
|
| Celiac Plexus | 1 | 1996 | 26 | 0.010 |
Why?
|
| Technetium Tc 99m Exametazime | 1 | 1996 | 68 | 0.010 |
Why?
|
| Emergencies | 1 | 2003 | 1170 | 0.010 |
Why?
|
| Forecasting | 1 | 2005 | 2951 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1997 | 829 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2004 | 2453 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1998 | 2255 | 0.010 |
Why?
|
| Health Behavior | 1 | 2008 | 2635 | 0.010 |
Why?
|
| Organotechnetium Compounds | 1 | 1996 | 137 | 0.010 |
Why?
|
| Neuronal Plasticity | 1 | 2005 | 1423 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 2000 | 934 | 0.010 |
Why?
|
| Software | 1 | 1990 | 4442 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 5135 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1998 | 1095 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2006 | 2926 | 0.010 |
Why?
|
| Testosterone | 1 | 2006 | 2419 | 0.010 |
Why?
|
| Neurotransmitter Agents | 1 | 1999 | 647 | 0.010 |
Why?
|
| Cell Count | 1 | 2000 | 1856 | 0.010 |
Why?
|
| Cholesterol | 1 | 2004 | 2919 | 0.010 |
Why?
|
| Cytokines | 1 | 2010 | 7323 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 2000 | 1235 | 0.010 |
Why?
|
| Mutation | 1 | 2000 | 29786 | 0.010 |
Why?
|
| Weight Loss | 1 | 2006 | 2625 | 0.010 |
Why?
|
| Oocytes | 1 | 2000 | 1188 | 0.010 |
Why?
|
| Oximes | 1 | 1996 | 311 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1998 | 1683 | 0.010 |
Why?
|
| Length of Stay | 1 | 1988 | 6311 | 0.010 |
Why?
|
| General Surgery | 1 | 2005 | 1636 | 0.010 |
Why?
|
| Spectrophotometry, Atomic | 1 | 1993 | 81 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 1991 | 5263 | 0.010 |
Why?
|
| Neuropeptides | 1 | 1999 | 942 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 2000 | 1701 | 0.010 |
Why?
|
| Basal Ganglia | 1 | 1996 | 546 | 0.010 |
Why?
|
| Models, Structural | 1 | 1993 | 361 | 0.010 |
Why?
|
| Species Specificity | 1 | 1998 | 2478 | 0.010 |
Why?
|
| Metals | 1 | 1998 | 719 | 0.010 |
Why?
|
| Molecular Probes | 1 | 1995 | 316 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 1998 | 1793 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 1998 | 1465 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2000 | 1257 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1996 | 1525 | 0.010 |
Why?
|
| Estradiol | 1 | 2000 | 2020 | 0.010 |
Why?
|
| Lanthanum | 1 | 1991 | 30 | 0.010 |
Why?
|
| Monitoring, Ambulatory | 1 | 1995 | 355 | 0.010 |
Why?
|
| Phosphocreatine | 1 | 1992 | 269 | 0.010 |
Why?
|
| Nigericin | 1 | 1991 | 8 | 0.010 |
Why?
|
| Motivation | 1 | 1982 | 1971 | 0.010 |
Why?
|
| Calcium-Transporting ATPases | 1 | 1991 | 123 | 0.010 |
Why?
|
| Glutaral | 1 | 1991 | 78 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1996 | 2008 | 0.010 |
Why?
|
| Fluorescence Polarization | 1 | 1991 | 132 | 0.010 |
Why?
|
| Thiocyanates | 1 | 1990 | 70 | 0.010 |
Why?
|
| Hydrogen | 1 | 1991 | 164 | 0.010 |
Why?
|
| Fluoresceins | 1 | 1990 | 235 | 0.010 |
Why?
|
| Oscillometry | 1 | 1990 | 147 | 0.010 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 1990 | 225 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2010 | 12209 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1993 | 15295 | 0.010 |
Why?
|
| Autoradiography | 1 | 1991 | 745 | 0.010 |
Why?
|
| Cell Membrane Permeability | 1 | 1991 | 590 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1990 | 821 | 0.010 |
Why?
|
| Pancreatitis | 1 | 1996 | 1092 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2005 | 6234 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2004 | 8551 | 0.010 |
Why?
|
| Paternalism | 1 | 1988 | 46 | 0.010 |
Why?
|
| Ataxia | 1 | 1991 | 304 | 0.010 |
Why?
|
| Massachusetts | 2 | 1994 | 8662 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 1993 | 13104 | 0.000 |
Why?
|
| Calcium Channel Blockers | 1 | 1991 | 692 | 0.000 |
Why?
|
| Child of Impaired Parents | 1 | 1992 | 455 | 0.000 |
Why?
|
| Light | 1 | 1994 | 1374 | 0.000 |
Why?
|
| Corpus Callosum | 1 | 1992 | 737 | 0.000 |
Why?
|
| Cross-Linking Reagents | 1 | 1991 | 694 | 0.000 |
Why?
|
| Patient Admission | 1 | 1994 | 1380 | 0.000 |
Why?
|
| Patient Advocacy | 1 | 1988 | 353 | 0.000 |
Why?
|
| Adenosine Triphosphate | 1 | 1991 | 2027 | 0.000 |
Why?
|
| Patient Care Team | 1 | 1996 | 2531 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1999 | 19233 | 0.000 |
Why?
|
| Tumor Cells, Cultured | 1 | 1991 | 6314 | 0.000 |
Why?
|
| Random Allocation | 1 | 1987 | 2428 | 0.000 |
Why?
|
| Radiography | 1 | 1993 | 7023 | 0.000 |
Why?
|
| Syndrome | 1 | 1987 | 3252 | 0.000 |
Why?
|
| Seizures | 1 | 1993 | 2859 | 0.000 |
Why?
|
| Phosphorylation | 1 | 1991 | 8437 | 0.000 |
Why?
|